Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.

ABSTRACT:

Aims

To examine the cost-effectiveness of hepatitis C virus (HCV) treatment of people who inject drugs (PWID), combined with medication-assisted treatment (MAT) and syringe-service programs (SSP), to tackle the increasing HCV epidemic in the United States.

Design

HCV transmission and disease progression models with cost-effectiveness analysis using a health-care perspective.

Setting

Rural Perry County, KY (PC) and urban San Francisco, CA (SF), USA. Compared with PC, SF has a greater proportion of PWID with access to MAT or SSP. HCV treatment of PWID is negligible in both settings.

Participants

PWID data were collected between 1998 and 2015 from Social Networks Among Appalachian People, U Find Out, Urban Health Study and National HIV Behavioral Surveillance Syst

SUBMITTER: Barbosa C 

PROVIDER: S-EPMC7751348 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature